China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the “Group”) is a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China, dedicated to offering competitive products and services to meet China's unmet needs for health and beauty. Since 28 September 2010, the Group has been listed on the Main Board of the Stock Exchange of Hong Kong Limited (stock code: 867), and included in the Morgan Stanley Capital International (MSCI) China Index, Hang Seng Healthcare Index, etc. The Group is the object of transaction in both Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, and also the largest shareholder of Tibet Rhodiola Pharmaceutical Holding Co. (stock code: 600211), a company listed on Shanghai Stock Exchange (A-share). The Group focuses on innovative products that are global first-in-class, or with the best efficacy, safety or cost-effectiveness in the class due to their innovative formulations or drug delivery systems, and has built an innovative product pipeline with relatively high innovation level, good market potential and competitive differentiation advantages. Meanwhile, the Group has proven and successful experience in drug commercialization and strong capability in professional academic promotion, having created a leading market position for many existing drugs and facilitated the clinical development of innovative drugs in China.